



KG JEBSEN CENTER  
for Cancer Immunotherapy

## **SEMINAR:**

### **"Fate's approach to off-the-shelf cancer immunotherapy"**

**Speaker: Bob Valamehr, Vice President, Cancer Immunotherapy, Fate Therapeutics Inc**

**Time: Friday, February 17<sup>th</sup>, 2017, 10:15h – 11:15h**

**Place: Institute for Cancer Research (Radiumhospital), Main Auditorium**

#### **About Fate Therapeutics:**

Fate is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Their pipeline is comprised of cell-based therapies for cancer and immune disorders. The cellular immunotherapies are based on their novel ex vivo cell programming approach, which is applied to modulate the therapeutic function and direct the fate of hematopoietic cells.

For more information: <http://fatetherapeutics.com/>

**The meeting is hosted by Professor Karl-Johan Malmberg, KG Jebsen Center for Cancer Immunotherapy and co-hosted by Oslo Cancer Cluster and Inven2**



OSLO CANCER  
CLUSTER

inven2